𝛼SK or Searchbullish
Aptorum_US: FDA Grants Orphan Drug Designation - SACT-1, First Patent for SACT-1-Cancer Treatment
Aptorum Group Ltd. [APM_US; US$60 million market cap] announced that the United States Food and Drug Administration (FDA) Office has granted Orphan...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Aptorum_US: FDA Grants Orphan Drug Designation - SACT-1, First Patent for SACT-1-Cancer Treatment21 Jan 2022
x